Saturday 17 October 2026
Export RGC’s income statement to Excel — free account
Regencell Bioscience Holdings Limited
RGC Healthcare Drug Manufacturers Specialty & Generic
Dividend growth for three consecutive years.
9.59
0.07
+0.74%
Follow RGC
Regencell Bioscience Holdings Limited (RGC) P/E ratio
Regencell Bioscience Holdings Limited has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| HIMS Hims & Hers Health, Inc. compare | n/m |
| AMLX Amylyx Pharmaceuticals, Inc. compare | n/m |
| RGC Regencell Bioscience Holdings Limited | n/m |
| INDV Indivior Pharmaceuticals Inc. compare | 11.2× |
| LQDA Liquidia Corporation compare | 21.9× |
| LNTH Lantheus Holdings, Inc. compare | 23.7× |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | 38.4× |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 73.4× |
| ALKS Alkermes plc compare | 102× |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)